Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH), sending the company’s shares up by 32%.
The findings showed that the 25mg dose of Ocaliva met the study’s primary endpoint of fibrosis improvement (1 stage) with no worsening of NASH at the planned 18-month interim analysis.
